产品
编 号：F202798
分子式：C36H35N3O4
分子量：573.68
分子式：C36H35N3O4
分子量：573.68
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 169545-27-1
产品详情
生物活性：
IRL 2500 is a potent Endothelin receptor antagonist. IRL 2500 shows IC50?values of 1.3 and 94 nM for ETB?and ETA?receptors, respectively. IRL 2500 inhibits ETB?receptor-mediated blood pressure increase and renal vascular resistance in rats?in vivo.
体内研究：
IRL 2500 (intravenous?injection;10 mg/kg) inhibits the initial transient decrease in mean arterial pressure (MAP) induced by the ETB-selective agonist IRL 1620 in rats, IRL 2500 also attenuates the IRL 1620-mediated increase in renal vascular resistance (RVR) in the anesthetized rat.IRL 2500 (intravenous?injection;10 mg/kg) pre-reatment significantly reduces the initial vasodepressor response to endothelin-1 (ET-1) and IRL 1620, however, it is not alters the secondary and sustained pressor response to these agonists.
IRL 2500 is a potent Endothelin receptor antagonist. IRL 2500 shows IC50?values of 1.3 and 94 nM for ETB?and ETA?receptors, respectively. IRL 2500 inhibits ETB?receptor-mediated blood pressure increase and renal vascular resistance in rats?in vivo.
体内研究：
IRL 2500 (intravenous?injection;10 mg/kg) inhibits the initial transient decrease in mean arterial pressure (MAP) induced by the ETB-selective agonist IRL 1620 in rats, IRL 2500 also attenuates the IRL 1620-mediated increase in renal vascular resistance (RVR) in the anesthetized rat.IRL 2500 (intravenous?injection;10 mg/kg) pre-reatment significantly reduces the initial vasodepressor response to endothelin-1 (ET-1) and IRL 1620, however, it is not alters the secondary and sustained pressor response to these agonists.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备